Metabolic stability and tumor inhibition of bombesin/GRP receptor antagonists

Thomas P Davis, S. Crowell, J. Taylor, D. L. Clark, D. Coy, J. Staley, T. W. Moody

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Small cell lung cancers (SCLC) synthesize and secrete bombesin/gastrin releasing peptide (BN/GRP). The autocrine growth cycle of BN/GRP in SCLC can be disrupted by BN/GRP receptor antagonists such as [Psi13,14]BN. Here several BN analogues were solid-phase synthesized and incubated with intact SCLC cells at 37°C in RPMI medium in a time-course fashion (0-1080 minutes) to determine enzymatic stability. The proteolytic stability of the compounds was determined by subsequent HPLC analysis. The metabolic half-life ranged from 154 minutes to 1388 minutes for the six analogues studied. [Psi13,14]BN was found to be very stable to metabolic enzymes (T 1 2 = 646 mm) and also inhibited SCLC xenograft formation in vivo in a dose-dependent manner. When [Psi13,14]BN was incubated with NCI-H345 cells, it inhibited 125I-GRP binding with an IC50 value of 30 nM. These data suggest that BN/GRP receptor antagonists such as [Psi13,14]BN may be useful for the treatment of SCLC.

Original languageEnglish (US)
Pages (from-to)401-407
Number of pages7
JournalPeptides
Volume13
Issue number2
DOIs
StatePublished - 1992

Fingerprint

Bombesin Receptors
Bombesin
Small Cell Lung Carcinoma
Tumors
Gastrin-Releasing Peptide
Neoplasms
Cells
Heterografts
Inhibitory Concentration 50
Half-Life
High Pressure Liquid Chromatography
Enzymes
Growth

Keywords

  • Bombesin
  • Gastrin releasing peptide
  • Half-life
  • Small cell lung cancer
  • Xenografts

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

Davis, T. P., Crowell, S., Taylor, J., Clark, D. L., Coy, D., Staley, J., & Moody, T. W. (1992). Metabolic stability and tumor inhibition of bombesin/GRP receptor antagonists. Peptides, 13(2), 401-407. https://doi.org/10.1016/0196-9781(92)90128-P

Metabolic stability and tumor inhibition of bombesin/GRP receptor antagonists. / Davis, Thomas P; Crowell, S.; Taylor, J.; Clark, D. L.; Coy, D.; Staley, J.; Moody, T. W.

In: Peptides, Vol. 13, No. 2, 1992, p. 401-407.

Research output: Contribution to journalArticle

Davis, TP, Crowell, S, Taylor, J, Clark, DL, Coy, D, Staley, J & Moody, TW 1992, 'Metabolic stability and tumor inhibition of bombesin/GRP receptor antagonists', Peptides, vol. 13, no. 2, pp. 401-407. https://doi.org/10.1016/0196-9781(92)90128-P
Davis, Thomas P ; Crowell, S. ; Taylor, J. ; Clark, D. L. ; Coy, D. ; Staley, J. ; Moody, T. W. / Metabolic stability and tumor inhibition of bombesin/GRP receptor antagonists. In: Peptides. 1992 ; Vol. 13, No. 2. pp. 401-407.
@article{e9beedddc3ec4043beff741620ff7be6,
title = "Metabolic stability and tumor inhibition of bombesin/GRP receptor antagonists",
abstract = "Small cell lung cancers (SCLC) synthesize and secrete bombesin/gastrin releasing peptide (BN/GRP). The autocrine growth cycle of BN/GRP in SCLC can be disrupted by BN/GRP receptor antagonists such as [Psi13,14]BN. Here several BN analogues were solid-phase synthesized and incubated with intact SCLC cells at 37°C in RPMI medium in a time-course fashion (0-1080 minutes) to determine enzymatic stability. The proteolytic stability of the compounds was determined by subsequent HPLC analysis. The metabolic half-life ranged from 154 minutes to 1388 minutes for the six analogues studied. [Psi13,14]BN was found to be very stable to metabolic enzymes (T 1 2 = 646 mm) and also inhibited SCLC xenograft formation in vivo in a dose-dependent manner. When [Psi13,14]BN was incubated with NCI-H345 cells, it inhibited 125I-GRP binding with an IC50 value of 30 nM. These data suggest that BN/GRP receptor antagonists such as [Psi13,14]BN may be useful for the treatment of SCLC.",
keywords = "Bombesin, Gastrin releasing peptide, Half-life, Small cell lung cancer, Xenografts",
author = "Davis, {Thomas P} and S. Crowell and J. Taylor and Clark, {D. L.} and D. Coy and J. Staley and Moody, {T. W.}",
year = "1992",
doi = "10.1016/0196-9781(92)90128-P",
language = "English (US)",
volume = "13",
pages = "401--407",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Metabolic stability and tumor inhibition of bombesin/GRP receptor antagonists

AU - Davis, Thomas P

AU - Crowell, S.

AU - Taylor, J.

AU - Clark, D. L.

AU - Coy, D.

AU - Staley, J.

AU - Moody, T. W.

PY - 1992

Y1 - 1992

N2 - Small cell lung cancers (SCLC) synthesize and secrete bombesin/gastrin releasing peptide (BN/GRP). The autocrine growth cycle of BN/GRP in SCLC can be disrupted by BN/GRP receptor antagonists such as [Psi13,14]BN. Here several BN analogues were solid-phase synthesized and incubated with intact SCLC cells at 37°C in RPMI medium in a time-course fashion (0-1080 minutes) to determine enzymatic stability. The proteolytic stability of the compounds was determined by subsequent HPLC analysis. The metabolic half-life ranged from 154 minutes to 1388 minutes for the six analogues studied. [Psi13,14]BN was found to be very stable to metabolic enzymes (T 1 2 = 646 mm) and also inhibited SCLC xenograft formation in vivo in a dose-dependent manner. When [Psi13,14]BN was incubated with NCI-H345 cells, it inhibited 125I-GRP binding with an IC50 value of 30 nM. These data suggest that BN/GRP receptor antagonists such as [Psi13,14]BN may be useful for the treatment of SCLC.

AB - Small cell lung cancers (SCLC) synthesize and secrete bombesin/gastrin releasing peptide (BN/GRP). The autocrine growth cycle of BN/GRP in SCLC can be disrupted by BN/GRP receptor antagonists such as [Psi13,14]BN. Here several BN analogues were solid-phase synthesized and incubated with intact SCLC cells at 37°C in RPMI medium in a time-course fashion (0-1080 minutes) to determine enzymatic stability. The proteolytic stability of the compounds was determined by subsequent HPLC analysis. The metabolic half-life ranged from 154 minutes to 1388 minutes for the six analogues studied. [Psi13,14]BN was found to be very stable to metabolic enzymes (T 1 2 = 646 mm) and also inhibited SCLC xenograft formation in vivo in a dose-dependent manner. When [Psi13,14]BN was incubated with NCI-H345 cells, it inhibited 125I-GRP binding with an IC50 value of 30 nM. These data suggest that BN/GRP receptor antagonists such as [Psi13,14]BN may be useful for the treatment of SCLC.

KW - Bombesin

KW - Gastrin releasing peptide

KW - Half-life

KW - Small cell lung cancer

KW - Xenografts

UR - http://www.scopus.com/inward/record.url?scp=0026637732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026637732&partnerID=8YFLogxK

U2 - 10.1016/0196-9781(92)90128-P

DO - 10.1016/0196-9781(92)90128-P

M3 - Article

VL - 13

SP - 401

EP - 407

JO - Peptides

JF - Peptides

SN - 0196-9781

IS - 2

ER -